On October 28, 2021, I presented on a panel at the annual Tobacco and Nicotine Products Regulation and Policy Conference sponsored by the Food and Drug Law Institute (FDLI).
As the recent national vice president for tobacco control for the American Cancer Society and a veteran of 33 years in efforts to combat the smoking epidemic, I’ve been encouraged to make available on Medium my remarks on how we can and must take a more sensible and humane approach to addressing tobacco use and vaping based on a continuum-of-risk approach.
I have reproduced them here. With FDLI’s generous permission, I’m also pleased to provide this YouTube link to the actual 13-minute presentation.
I’m pleased to be a part of this panel covering some cutting-edge issues around the eclectic marketplace for tobacco and nicotine products. I’ll use my time to address a few current issues that strike me as worthy of attention in this forum.
Let me begin on a personal note. Vaping has affected me personally, as I know it has some of you. Back when what was named “EVALI” sickened more than 2,000 people and took the lives of more than 60 of them, there were constant news reports and statements by some in the public health community that alarmingly, but erroneously, conflated concerns with youth nicotine vaping and the lethal events caused by illicit use of devices containing THC and vitamin E acetate.
Cliff Douglas – Medium.com – 2021-12-08.
Want More Investigative Content?
